GEF-Inhibitors: New small molecules for the treatment of autoimmune and malignant diseases
Scientists at the University of Bonn have identified new small molecules which can be used for the treatment of diseases characterized by alterations of proteins which are affected by Guanine nucleotide Exchange Factors (GEFs). Proteins targeted by GEFs are involved in integrin signalling, vesicle transport, or MAPK-signalling. These processes play an important role in the modulation of the immune response. Therefore, abnormal activation of the target proteins of GEFs can cause autoimmune and tumor diseases in humans.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Red light therapy for repairing spinal cord injury passes milestone
Patients with spinal cord injury (SCI) could benefit from a future treatment to repair nerve connections using red and near-infrared light. The method, invented by scientists at the University of…
Insect research is revolutionized by technology
New technologies can revolutionise insect research and environmental monitoring. By using DNA, images, sounds and flight patterns analysed by AI, it’s possible to gain new insights into the world of…
X-ray satellite XMM-newton sees ‘space clover’ in a new light
Astronomers have discovered enormous circular radio features of unknown origin around some galaxies. Now, new observations of one dubbed the Cloverleaf suggest it was created by clashing groups of galaxies….
